E. L. Gispert

High-impact medicines, system sustainability and the role of access management: evidence from Catalonia

Background The reimbursement of high-impact medicines (HIMs) poses growing clinical and budgetary challenges for publicly funded health systems. In Catalonia, pharmaceutical spending has increased considerably in recent years, driven by the uptake of high-cost therapies and expanded indications under clinical and econo...